你即將離開本站

並前往https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext

Efficacy and safety of a novel dual GIP and GLP-1 receptor ...

A 2-year carcinogenicity study in rats is ongoing. One limitation of the SURPASS-1 trial was the relatively short duration of 40 weeks. A longer ...

確定！ 回上一頁

查詢 「SURPASS study」的人也找了：

  1. SURPASS study
    2.
  2. Tirzepatide
    3.
  3. SURPASS-3 tirzepatide
    4.
  4. SURPASS 4 tirzepatide
    5.
  5. Tirzepatide lancet
    6.
  6. Tirzepatide a potential new agent for type 2 diabetes
    7.
  7. SURPASS-CVOT
    8.
  8. Tirzepatide FDA
    9.